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Three  studies  were  performed  to  determine  the  duration  of  immunity  of  the  bovine  viral  diarrhea  virus
type 1 and  type  2 (BVDV-1  and  BVDV-2)  and bovine  herpesvirus-1  (BHV-1)  fractions  of a commercially
prepared  modiﬁed-live  vaccine.  Vista® Once  SQ  (Vista®) vaccine  contains  ﬁve modiﬁed-live  viruses,
BVDV-1,  BVDV-2,  BHV-1,  bovine  respiratory  syncytial  virus,  and  bovine  parainﬂuenza  3 virus,  and  two
modiﬁed-live  bacteria,  Pasteurella  multocida  and  Mannheimia  haemolytica.  For  all  three  studies,  calves
were  administered  a single  dose  of  vaccine  or placebo  vaccine  subcutaneously,  and  were  challenged
with  one  of the three  virulent  viruses  at least  one  year  following  vaccination.  Calves  were  evaluated  daily
following  challenge  for  clinical  signs  of disease  associated  with viral  infection,  nasal  swab  samples  were
evaluated  for  virus  shedding,  and  serum  was  tested  for neutralizing  antibodies.  Following  the  BVDV-1
and  BVDV-2  challenges,  whole  blood  was evaluated  for white  blood  cell counts,  and  for  the  BVDV-2  study,
whole  blood  was  also  evaluated  for platelet  counts.  Calves  vaccinated  with  BVDV  type  1a,  were  protected
from  challenge  with  BVDV  type  1b,  and had signiﬁcant  reductions  in clinical  disease,  fever,  leukopenia,
and  virus  shedding  compared  to control  calves.  Vaccinated  calves  in  the BVDV-2  study  were  protected
from  clinical  disease,  mortality,  fever,  leukopenia,  thrombocytopenia,  and virus  shedding  compared  to
controls.  Vaccinated  calves  in  the  BHV-1  study  were  protected  from  clinical  disease  and  fever,  and  had
signiﬁcantly  reduced  duration  of nasal  virus  shedding.  These  three  studies  demonstrated  that  a  single
administration  of  the  Vista® vaccine  to  healthy  calves  induces  protective  immunity  against  BVDV-1,
BVDV-2  and BHV-1  that  lasts  at least  one  year  following  vaccination.
ublis© 2016  The  Authors.  P
. Introduction
Bovine viral diarrhea viruses (BVDV) and BHV-1 are among the
ost important viral pathogens of cattle worldwide. Infections
ith any of these viruses in naive herds can result in severe disease
nd signiﬁcant economic loss to producers [1–3]. These viruses are
requently contributing factors in bovine respiratory disease com-
lex, which costs the US cattle industry more than a billion dollars
ach year [3–5].
BVDV viruses are antigenically heterogeneous, with at least two
ecognized genotypes (BVDV-1 and BVDV-2), and subgenotypes
ithin each genotype [6]. BVDV-1b is currently the predominant
irculating type 1 subgenotype in the US [7,8]. For this BVDV-1
tudy, calves were vaccinated with Vista®, containing a BVDV-1a
ubgenotype, and were challenged with a BVDV-1b subgenotype.
∗ Corresponding author. Tel.: +1 9134226865.
E-mail address: lisa.purtle@merck.com (L. Purtle).
ttp://dx.doi.org/10.1016/j.vaccine.2016.02.009
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article
.0/).hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Previous studies have demonstrated protection in calves vacci-
nated with BVDV-1a against challenge with BVDV-1b six months
following vaccination [9], and protection of fetuses against per-
sistent infection with BVDV-1b when the heifers were vaccinated
prior to breeding with BVDV-1a [10]. Infection with BVDV-1 or
BVDV-2 can cause a variety of clinical disease syndromes, and even
death [11,12].
Infection with bovine herpesvirus 1 (BHV-1) frequently results
in upper respiratory tract disease, often referred to as infectious
bovine rhinotracheitis (IBR), and BHV-1 also causes a wide range of
clinical conditions in cattle [3,13,14]. BHV-1 establishes latency in
the neural tissues following primary infection [15]. Reactivation of
latent BHV-1 may  be triggered by stressors, and reactivated virus
is shed and can be transmitted to other animals [16,17]. Vaccina-
tion considerably reduces the amount of virus excreted following
reactivation [18–20].
Vaccination plays a critical role in the control of both BVDV
and BHV-1 infections and disease. Killed and modiﬁed live (MLV)
vaccines are frequently used in both BVDV and BHV-1 control
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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rograms, but MLV  vaccines are generally considered to be supe-
ior to killed vaccines with respect to efﬁcacy, as MLV  vaccines are
sually better at stimulating neutralizing antibody production and
ymphocyte proliferation, and MLV  vaccines provide higher levels
f T cell memory and heterologous protection [21–27].
The purpose of these studies was to determine if immunity
rovided by a single subcutaneous (SQ) vaccination of MLV  BVDV-
, BVDV-2 and BHV-1, to healthy seronegative calves, provides
rotection against virulent challenge at least one year following
accination.
. Materials and methods
To determine the long-term immunity of the Vista® BVDV-1,
VDV2, and BHV-1 fractions, three separate immunogenicity stud-
es were conducted. For each study, calves were administered a
ingle dose of vaccine or placebo at approximately 3 months of
ge, and challenged with virulent virus approximately one year
ollowing vaccination.
.1. Animal welfare and humane endpoints
These studies were carried out in accordance with the National
esearch Council’s Guide for the Care and Use of Laboratory Ani-
als, Eighth Edition, 2011. All three studies described in this paper
ere approved by the Institutional Animal Care and Use Commit-
ee of Merck Animal Health (MAH), De Soto, Kansas, and all animals
ere under the care of a licensed Veterinarian.
Following challenge with highly virulent BVDV-2, calves were
valuated at least twice daily, and the decision to euthanize calves
ith severe clinical illness or distress was made by the Attending
eterinarian, in an effort to minimize suffering. The calves were
umanely euthanized by intravenous barbiturate overdose.
.2. Calves and vaccination
Prior to vaccination, ear notch samples from all calves were sent
o Iowa State University Veterinary Diagnostic Laboratory (Ames,
A), all calves tested negative for BVDV persistent infection by
mmunohistochemistry. For vaccination and up until challenge, the
alves from all three studies were housed in separate open-sided
arns, in pens with 4 or 5 calves per pen. Vaccinated and control
alves were housed together, as previous studies have demon-
trated that calves vaccinated with Vista® do not shed virus. For
ll three studies, calves were vaccinated with a single 2 mL  dose
f Vista® by the SQ route in the left neck, using a 20 gauge x 1 inch
eedle.
For the BVDV-1 study, 34 Angus calves at 3–4 months of
ge were randomly assigned to two treatment groups, with 22
accinates and 12 controls. Calves in the vaccinate group were
dministered experimental Serial # 07Dec2011-B, containing min-
mum dose levels of the BVDV-1 and BVDV-2 fractions, and release
evels or higher of all other antigen fractions. Calves in the control
roup were vaccinated with a placebo vaccine, containing the same
omponents as the vaccine, but without the BVDV-1 and BVDV-2
ractions.
For the BVDV-2 study, 40 colostrum-deprived (CD) Holstein
alves at 3 months of age were randomly assigned to two treatment
roups, with 20 vaccinates and 20 controls. Calves in the vaccinate
roup were administered experimental Serial # 18April2012-1,
ontaining minimum levels of the BVDV-1 and BVDV-2 fractions,
nd release levels or higher of all other antigen fractions. Control
alves were vaccinated with a placebo vaccine, containing the same
omponents as the vaccine, but without the BVDV-1 and BVDV-2
ractions. (2016) 1582–1588 1583
For the BHV-1 study, 40 CD Holstein calves at 3 months of
age were randomly assigned to two treatment groups, with 20
vaccinates and 20 controls. Calves in the vaccinate group were
administered experimental Serial # 25April2012-1, containing
minimum dose levels of BHV-1, and release levels or higher of
the other antigen fractions. Control calves were vaccinated with
a placebo vaccine, containing the same components as the vaccine,
but without the BHV-1 fraction. One vaccinated calf in the BHV-
1 study died prior to challenge due to complications of repeated
bloating.
2.3. Challenge
For each study, calves were moved to and housed together in
a dry lot with a loaﬁng shed just prior to challenge, and remained
there until the end of the study. The challenges for each study were
administered by spraying 2 mL  of virus into each nostril (4 mL  total
volume) using an atomizer (Devilbiss, Somerset, PA). For the BVDV-
1 study, 34 calves were challenged intranasally (IN) 365 days post-
vaccination with non-cytopathic BVDV-1b strain T1186a, obtained
from National Veterinary Services Laboratory (Ames, IA). Each calf
received 6.7 Log10 50% tissue culture infectious dose (TCID50).
For the BVDV-2 study, 40 calves were challenged IN 384 days
post-vaccination with non-cytopathic BVDV2 strain 1373 (Dr. Julia
Ridpath, National Animal Disease Center, Ames, IA). Each calf
received 5.9 Log10 TCID50.
For the BHV-1 study, 19 vaccinated and 20 control calves
were challenged IN 364 days following vaccination with IBR strain
Cooper, obtained from the Center for Veterinary Biologics Labora-
tories (Ames, IA). Each calf received 6.0 Log10 TCID50.
2.4. Evaluation of clinical signs
Clinical signs of disease were evaluated by investigators who
were blinded to the vaccination status of the calves. Calves from all
studies were evaluated daily for clinical signs for 2 or 3 days prior
to challenge to establish baseline parameters, and daily from days
1 through 14 following challenge. Clinical assessments were made
by investigators at approximately the same time every morning,
and rectal temperatures were monitored. For the BVDV studies, an
affected calf was  deﬁned as one with moderate to severe diarrhea,
nasal discharge, depression, dyspnea, mucosal or oral lesions, or
death on any post-challenge day. For the BHV-1 study, an affected
calf was  deﬁned as one with moderate to severe nasal or ocu-
lar discharge, cough, depression, dyspnea, or nasal lesions on any
post-challenge day. Clinical signs were noted as mild, moderate, or
severe, according to Table 1.
2.5. Sample collections
For each study, blood samples for serum were collected prior to
vaccination, every other month following vaccination, just prior to
challenge, and seven and fourteen days post-challenge, to test for
VN antibody titers to BVDV-1, BVDV-2 or BHV-1, for each respective
study.
Nasal swab samples were collected just prior to vaccination and
challenge, and daily for at least ten days following challenge, and
were stored at −70 ◦C or colder until they were tested for the pres-
ence of virus, as described previously [9].
For the BVDV studies, blood was  collected in EDTA tubes for
three days prior to challenge, and daily after challenge for at
least ten days. The blood was tested for white blood cell (WBC)
counts using a HemaTrue® Blood Analyzer (HESKA Corporation,
Loveland, CO). For the BVDV-2 study, platelet counts were also
determined from the same EDTA blood samples. Baseline WBC
and platelet counts were determined by averaging the counts from
1584 L. Purtle et al. / Vaccine 34 (2016) 1582–1588
Table 1
Description of the clinical signs of disease.
Clinical
score
Nasal/Ocular
discharge
Depression Diarrhea Dyspnea Mucosal or oral
lesions
Anorexia Cough
Normal None Normal in attitude
and activities
Normal feces Normal breathing No nasal or oral
lesions
Normal appetite None
Mild  Serous discharge Moves slowly, head
down
Soft, slightly loose
feces
Slight difﬁculty
breathing, short
and rapid
White colored
lesions
Slightly off feed <3 episodes
occasional cough
Moderate Mucopurulent
discharge
Tends to lie down,
moves reluctantly
Watery diarrhea Labored breathing,
noticeable
abdominal
Red lesions Moderately off
feed
>3 episodes
repeated cough
Severe  Copious
mucopurulent
discharge
Stands with
difﬁculty or not at
all, little or no
Watery and bloody
diarrhea
Very labored,
grunting or raspy
breathing
Bloody, ulcerated
lesions
Not eating NA
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lood samples collected three days prior to challenge. Leukopenia
as deﬁned as a WBC  count <60% of the baseline count, and/or
4.0 × 103 WBC/L. Thrombocytopenia was deﬁned as a platelet
ount <60% of the baseline count, and/or <100 × 103 platelets/L.
.6. Virus neutralizing antibody analysis
The VN antibody titers were measured using standard microtiter
late assays on bovine kidney cells (MDBK), as described previously
9]. The viruses used in the VN assays were all cytopathic; BVDV-
 strain Singer, BVDV-2 strain 125cp, and BHV-1 strain RK23. The
ndpoint VN antibody titer of each sample was calculated as the
eciprocal of the highest serum dilution that inhibited CPE in 50%
f the wells, using the Spearman-Karber method.
.7. Nasal virus isolation
Virus isolation from nasal swabs was conducted as described
reviously [9]. After incubation of the nasal swab samples on MDBK
ell monolayers, the BVDV-1 and BVDV-2 plates were ﬁxed and
eacted with BVDV-1 speciﬁc monoclonal antibody (MAb) 4e1 [28]
r BVDV-2 speciﬁc MAb  BA-2 [29], respectively, then reacted with
uorescein-conjugated mouse anti-IgG, and observed microscop-
cally to determine the 50% ﬂuorescent antibody infectious dose
FAID50) per mL.  After incubation, the BHV-1 plates were observed
or typical cytopathic effect (CPE) to determine the TCID50/mL.
.8. Data analysis
In each study, the two treatment groups (vaccinates and con-
rols) were statistically analyzed and compared with respect to
he clinical signs of disease, fever, nasal virus shedding, and (for
VDV) WBC  and platelet counts. The p-values were associated with
xact Conﬁdence Intervals: Inverting two one-sided tests using the
tatXact BINOMIAL procedure in SAS® Version 9.1.3. The prevented
raction and 95% conﬁdence intervals were calculated using R-3.0.1
F module executed in SAS® 9.3.1 with the procedure PROC R.
or mitigated fraction analysis, the Wilcoxon Rank Sum Test and
able 2
eometric mean and range of VN antibody titers against BVDV-1 in vaccinated and contr
Group Vaccination 1 month 2 months 4 months 6 months 8
Vaccinate <2 252
(32–362)
2763
(512–>4096)
3338
(724–>4096)
1471
(181–>4096)
2
(
Control  <2 <2 <2 <2 <2 <two-sided p-value were computed using the StatXact TWOSAMPL
procedure in SAS® 9.3.1.
3. Results
3.1. Serological results
For all three studies, all calves were VN antibody negative to
BVDV-1, BVDV-2 and BHV-1 prior to vaccination, and all con-
trol calves remained seronegative throughout the post-vaccination
period, and up until 14 days post-challenge.
For the BVDV1 and BVDV-2 studies, all vaccinated calves
responded serologically to vaccination, and all calves still had
detectable VN antibody titers to BVDV-1 and BVDV-2 at the time
of challenge, at least one year following vaccination. Vaccinated
calves in both studies responded to challenge with strong anamnes-
tic VN antibody responses by 7 days post-challenge. Geometric
mean VN antibody titers against BVDV-1 and BVDV-2 are shown
in Tables 2 and 3.
For the BHV-1 study, 19 of 20 vaccinated calves developed
detectable VN antibody titers to BHV-1 following vaccination, and
at challenge (one year following vaccination), 15 of 19 vaccinated
calves still had detectable VN antibody titers to BHV-1. All 20 vac-
cinated calves responded with anamnestic antibody responses to
BHV-1 by 7 days post-challenge. Geometric mean VN antibody
titers against BHV-1 are shown in Table 4.
3.2. Efﬁcacy of vaccination against BVDV-1
For the BVDV-1 study, 6 of 12 (50%) control calves exhibited
clinical signs of disease caused by BVDV-1 following challenge,
including moderate to severe diarrhea, nasal discharge, and/or
depression, whereas only one calf of 22 (<5%) in the vaccinated
group had only moderate diarrhea on a single day post-challenge.
Statistical analysis of the data demonstrated that vaccination aided
in the prevention of clinical disease caused by BVDV-1 (p = 0.0030).
Control calves had signiﬁcantly higher (p ≤ 0.0001) maximum
mean post-challenge rectal temperatures (104.8 ◦F) compared to
vaccinated calves (102.7 ◦F). Eleven of 12 (92%) control calves had
ol animals.
 months 10 months Challenge 7 days
post-challenge
14 days
post-challenge
083
256–>4096)
2251
(256–>4096)
1805
(362–>4096)
1403
(181–>4096)
>4096
(4096–>4096)
2 <2 <2 <2 76
(23–181)
ine 34 (2016) 1582–1588 1585
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ever (deﬁned as a temperature >103.5 ◦F for this study) on at least
ne post-challenge day. Three of 22 (14%) vaccinated calves had
ever during the post-challenge period, but two of those calves also
ad fever prior to challenge. The mean daily post-challenge rectal
emperatures for vaccinates and controls are shown in Fig. 1A.
All 12 (100%) control calves developed leukopenia following
hallenge, and were leukopenic for a mean duration of 4 days,
ith a range of 1–6 days. Only 2 of 22 (9%) vaccinated calves were
eukopenic following challenge, each on only a single day. Statisti-
al analysis demonstrated that vaccination aided in the prevention
f leukopenia caused by BVDV-1 (p ≤ 0.0001). The mean daily post-
hallenge WBC  counts for vaccinates and controls are shown in
ig. 1B.
BVDV-1 was isolated from the nasal secretions of 11 of 12
92%) control calves following challenge, for a mean duration of
.8 days, with a range of 1–6 days duration. BVDV-1 was  not iso-
ated from any of the 22 (0%) vaccinated calves on any day following
hallenge. Analysis of the data demonstrated that vaccination pre-
ented BVDV-1 nasal virus shedding (p ≤ 0.0001). The mean daily
ost-challenge nasal swab BVDV-1 titers for vaccinates and con-
rols are shown in Fig. 1C.
.3. Efﬁcacy of vaccination against BVDV-2
For the BVDV-2 study, 20 of 20 (100%) control calves exhib-
ted moderate to severe clinical signs of disease caused by BVDV-2
ollowing challenge, including moderate to severe diarrhea, nasal
ischarge, depression, dyspnea, and oral lesions, and 18 of the 20
90%) control calves died (n = 12) or were euthanized (n = 6) due
o severe BVDV-2 clinical disease between day 11 and 16 post-
hallenge. Two of 20 (10%) vaccinated calves had only moderate
asal discharge post-challenge, and all vaccinated calves were alive
nd healthy on day 16 post-challenge. Statistical analysis of the clin-
cal disease and mortality data demonstrated that vaccination aided
n the prevention of clinical disease caused by BVDV-2 (p ≤ 0.0001),
nd death following challenge (p ≤ 0.0001).
All 20 (100%) control calves had fever (deﬁned as a temperature
104.0 ◦F for this study) following challenge, for a mean dura-
ion of 4.4 days, whereas only 5 of 20 (25%) vaccinated calves had
ever, each on only one day. The control calves also had signiﬁ-
antly higher (p ≤ 0.0001) mean maximum post-challenge rectal
emperatures (106.1 ◦F) compared to vaccinated calves (103.3 ◦F).
he mean daily post-challenge rectal temperatures for vaccinates
nd controls are shown in Fig. 2A.
Following challenge, 19 of 20 (95%) control calves were
eukopenic for a mean duration of >7 days, whereas only 3 of
0 (15%) vaccinated calves were leukopenic for 1–3 days. 18
f 20 (90%) control calves were thrombocytopenic for a mean
uration of >5 days, and 9 of 20 (45%) vaccinated calves were
hrombocytopenic for a single day each. Statistical analysis of the
ata demonstrated that vaccination aided in the prevention of
eukopenia (p ≤ 0.0001) and thrombocytopenia (p = 0.0024) caused
y BVDV-2. The mean daily post-challenge WBC  and platelet counts
or vaccinates and controls are shown in Fig. 2B and C.
All 20 of 20 (100%) control calves shed BVDV-2 from nasal sec-
etions post-challenge, for a mean duration of 5 days. None of the
0 (0%) vaccinated calves shed virus on any day post-challenge,
ndicating that vaccination prevents BVDV-2 nasal virus shedding
p ≤ 0.0001). The mean daily post-challenge nasal swab BVDV-2
iters for vaccinates and controls are shown in Fig. 2D.
.4. Efﬁcacy of vaccination against BHV-1For the BHV-1 study, 18 of 20 (90%) control calves exhibited clin-
cal signs of disease caused by BHV-1 following challenge, including
evere nasal discharge, dyspnea, and/or nasal lesions. Only one of
Fig. 1. BVDV-1 Study Results. Calves vaccinated with a BVDV-1a MLV  vaccine were
protected from challenge with BVDV-1b, one year after vaccination. (A) Mean rec-
tal temperatures post-challenge (with one standard error); (B) mean WBC  counts
post-challenge (with one standard error); and (C) mean nasal virus shedding (Log10
FAID50/mL) post-challenge (with one standard error).
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Table 3
Geometric mean and range of VN antibody titers against BVDV-2 in vaccinated and control animals.
Group Vaccination 1 month 2 months 4 months 6 months 8 months 10 months Challenge 7 days
post-challenge
14 days
post-challenge
Vaccinate <2 11
(<2–128)
304
(11–2896)
315
(11–2048)
126
(11–1024)
97
(6–724)
135
(11–1024)
59
(11–512)
304
(45–2048)
2313
(256–>5793)
Control <2 <2 <2 <2 <2 <2 <2 <2 <2 34
(<2–512)
Table 4
Geometric mean and range of VN antibody titers against BHV-1 in vaccinated and control animals.
Group Vaccination 1 month 2 months 4 months 6 months 8 months 10 months Challenge 7 days
post-challenge
14 days
post-challenge
Vaccinate <2 15
(<2–45)
9
(<2–45)
5
(<2–32)
4
(<2–16)
5
(<2–23)
6
(<2–23)
4
(<2–11)
17
(6–181)
313
(181–362)
Control <2 <2 <2 <2 <2 <2 <2 <2 <2 101
(45–256)
Fig. 2. BVDV-2 Study Results. Calves vaccinated with a BVDV-2 MLV vaccine were protected from challenge with highly virulent BVDV-2, more than one year after vaccination.
(A)  Mean rectal temperatures post-challenge (with one standard error); (B) mean WBC  counts (with one standard error); (C) mean platelet counts (with one standard error);
and  (D) mean nasal virus shedding (Log10 FAID50/mL) post-challenge (with one standard error).
L. Purtle et al. / Vaccine 34
Fig. 3. BHV-1 Study Results. Calves vaccinated with a BHV-1 MLV  vaccine were
protected from challenge with virulent BHV-1, one year after vaccination. (A) Per-
centage of calves with clinical disease (incidence) on all post-challenge days; (B)
mean rectal temperatures post-challenge (with one standard error); and (C) mean
nasal virus shedding (Log10 TCID50/mL) post-challenge (with one standard error). (2016) 1582–1588 1587
19 (5%) calves in the vaccinate group had severe nasal discharge
following challenge. Statistical analysis of the data demonstrated
that vaccination aided in the prevention of clinical disease caused
by BHV-1 (p ≤ 0.0001). The daily post-challenge incidence of clini-
cal disease caused by BHV-1 for vaccinates and controls is shown
in Fig. 3A.
Twenty of 20 (100%) control calves had fevers ≥103.5 ◦F post-
challenge, with a mean duration of 2.9 days, whereas 9 of 19 (47%)
vaccinated calves developed fevers post-challenge, with a mean
duration of 1.4 days. The control calves also had signiﬁcantly higher
incidence of fever compared to vaccinated calves (p ≤ 0.0001). The
mean maximum post-challenge temperatures were 104.6 ◦F for
the control calves, and 103.4 ◦F for the vaccinated calves. The
post-challenge mean daily rectal temperatures for vaccinates and
controls are shown in Fig. 3B.
All vaccinated and control calves shed BHV-1 in nasal sec-
retions following challenge, but the vaccinated calves shed virus
for a mean duration of 7 days, whereas all control calves were
still shedding virus ten days post-challenge (nasal swab samples
were not collected after ten days post-challenge). Statistical anal-
ysis demonstrated that vaccination reduced the duration of BHV-1
nasal virus shedding (p ≤ 0.0001). The mean post-challenge daily
nasal swab BHV-1 titers for vaccinates and controls are shown in
Fig. 3C.
4. Discussion
Although BVDV and BHV-1 viruses were ﬁrst identiﬁed at least
60 years ago, they are still among the most important pathogens
globally, and continue to have a signiﬁcant impact on cattle health
and welfare. BVDV viruses can be difﬁcult to control because of their
antigenic heterogeneity [6], and BHV-1 can persist in cattle popu-
lations long-term due to its ability to become latent, reactivate,
and be readily transmitted between animals [14,16]. Vaccination
against these viruses is critical for the control of infections and
disease. A duration of immunity of at least one year following vac-
cination is essential to provide protection to cattle under typical
annual revaccination programs.
These studies conﬁrmed that vaccination with minimum levels
of BVDV1 and BVDV-2 provided protection against clinical dis-
ease and infection one year following vaccination. Additionally, the
BVDV-1a strain in the vaccine provided protection against a BVDV-
1b strain. Minimum dose levels of BHV-1 also provided protection
against clinical disease one year after vaccination, but did not pre-
vent viral infection and nasal shedding, which is consistent with
data showing that conventional BHV-1 vaccines do not appear to
reduce the prevalence of infection [30]. However, vaccinated calves
had signiﬁcantly reduced duration of BHV-1 shedding compared to
control calves.
Calves vaccinated with a single dose of Vista® Once SQ were
either completely protected, or had signiﬁcantly less clinical dis-
ease and virus shedding following challenge with virulent BVDV-1,
BVDV-2, or BHV-1 at least one year following vaccination, when
compared to control calves. As vaccines are manufactured to be at
least 10 times higher than minimum protective dose levels, it is
expected that the vaccines released for commercial use will induce
similar or possibly even longer lasting immunity.
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